loading

IMPORTANT RISK INFORMATION

Who should NOT take NAMENDA XR?

NAMENDA XR should not be taken by anyone who is allergic (hypersensitive) to memantine, the active substance in NAMENDA XR, or who has had a bad reaction to NAMENDA XR or any of its ingredients.

What should be discussed with the healthcare provider before taking NAMENDA XR?

Before starting NAMENDA XR, talk to the healthcare provider about all of the patient's past and present medical conditions, including:

  • Seizure disorders
  • Difficulty passing urine
  • Liver, kidney, or bladder problems

If the patient is taking other medications (including those without a prescription), ask the healthcare provider if NAMENDA XR is right for the patient.

  • Certain medications, changes in diet, or medical conditions may affect the amount of NAMENDA XR in the body and possibly increase side effects.

What are the possible side effects
of NAMENDA XR?

The most common side effects associated with NAMENDA XR treatment are headache, diarrhea, and dizziness. This is not a complete list of side effects.

INDICATION

NAMENDA XR extended-release capsules are approved for the treatment of moderate to severe Alzheimer's disease. NAMENDA XR is available by prescription only.

You are encouraged to report negative side effects of prescription drugs to the FDA.
Visit www.FDA.gov/
medwatch
or call 1-800-FDA-1088.

Please see full Prescribing Information, including
Patient Information
.

Actavis Logo

NAMENDA ®,
NAMENDA XR ® and their designs are registered trademarks of Merz Pharma GmbH & Co. KGaA. Actavis™ and its design are trademarks of Actavis, Inc. or its affiliates.
© 2015 Actavis. All rights reserved. NXR27809 03/15